<DOC>
	<DOCNO>NCT01673607</DOCNO>
	<brief_summary>The immune response primary tumor major role prognosis colorectal cancer ( CRC ) . Some study suggest prognosis value cytotoxic T cell memory T cell primary tumor great tumoral stage . There work literature examine prognosis value immune response liver metastasis . To study immune cell ( histology ) inflammatory response ( cytokine ) liver metastasis challenge understand effectiveness chemotherapy use situation . The chemotherapy use liver metastases colorectal cancer also effect non-tumoral liver tumor therefore interfere postoperative complication hepatic resection . Sinusoidal dilatation present 20 % 80 % patient receive oxaliplatin hepatectomy . Steatosis frequently observe administration 5-FU alone combination irinotecan . This steatosis may also accompany inflammatory lesion ( steatohepatitis ) , especially administration oxaliplatin irinotecan associate increase postoperative mortality . The hepatic toxicity new biological agent well know ( cetuximab bevacizumab ) . The mechanisms chemotherapy-induced toxicity currently unknown . The main objective analyze profile immune response liver metastases CRC find link radiological response . Measurements make quantitative RT-PCR frozen liver biopsy . Secondary objective seek correlation histological lesion induce chemotherapy non-invasive test liver fibrosis . The secondary endpoint rate immune cell , histologic response ( percentage tumor necrosis ) , disease-free survival , non-invasive test fibrosis , chemotherapy-induced liver injury , cytokine circulate angiogenic factor .</brief_summary>
	<brief_title>Study Immune Response Liver Damage Induced Chemotherapy Liver Metastases Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patient old 18 year . Patients histologically proven colorectal cancer resectable potentially resectable liver metastasis . First line chemotherapy alone combination intravenous 5FU , oral 5FU ( capecitabine ) , oxaliplatin , irinotecan , cetuximab , panitumumab bevacizumab ( LV5FU2 , XELODA , FOLFIRI , FOLFOX , XELOX , XELIRI alone combination either cetuximab panitumumab bevacizumab ) . Signature informed consent . Patient affiliate French Social Security . Patients take immunosuppressive therapy . Lack measurable tumoral target . Patients contreindication chemotherapy use : oxaliplatin , irinotecan , fluorouracil , capecitabine , cetuximab , panitumumab , bevacizumab . Patients hospitalize without consent . Patients emergency situation . Patients guardianship . Patients deprive liberty judicial administrative procedure . Pregnant nursing woman , woman without effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>